Oncology
Latest Content
Redefining ‘druggability’ with multi-modal target ID screening
As drug discovery demands ever closer analysis to ensure quality and validation of drug targets, Dr Benedict Cross looks at how to use a multi-modal approach to explore and identify drug-mimetics in …
News
Trust-based not-for-profit biobank platform will offer left-over biosamples to biotech and Pharma researchers
Left-over clinical material like blood samples and excised tissue may be medical waste, but it can also be research treasure. This material is needed by researchers for the development of new drugs, …
In Depth
Redefining ‘druggability’ with multi-modal target ID screening
As drug discovery demands ever closer analysis to ensure quality and validation of drug targets, Dr Benedict Cross looks at how to use a multi-modal approach to explore and identify drug-mimetics in …
Comment And Analysis
“Let’s not wait another 100 years to collaborate” appeals President of The Pistoia Alliance
The breakthroughs in vaccine development that have been achieved in just ten months clearly demonstrate the value of working together across biopharma and how collaboration can produce hugely valuabl…
Interviews
Foundational science of the future
Traditionally pharma has been focused on developing small molecules and chemicals. Here, David Ferrick gives his view on immunology and cell therapy as a rapidly emerging pillar of science and therap…
